Interventional Glaucoma

The company’s iCare HOME2 self-tonometer allows patients to collect real-world IOP data at any time.

Novel trial design will compare safety and effectiveness outcomes for the OMNI Surgical System and the iStent inject in lowering IOP as a standalone treatment option without concomitant cataract surgery.

Vanderbilt’s David Calkins, PhD, was honored with the 2022 President’s Award, presented by the Glaucoma Research Foundation, at the Glaucoma 360 Annual Gala last month.

Raj Kannan, the new CEO of Aerie Pharmaceuticals, talks with Ophthalmology Times' David Hutton about what's coming down the pipeline for Aerie.

Drug is prescribed as adjunctive therapy for those with glaucoma

"Tell Me Your Secrets" is the theme of the virtual April 2 event, which is expected to build on the foundation established during the first program held last fall.

The study, conducted with Tufts Medical Center, represents a breakthrough showing that Microdose Array Print technology can provide similar benefits of non-preserved medications.

Lisa M. Nijm, MD, JD, previews the program for this April 2 virtual event designed to help young ophthalmologists learn everything they need to know when starting practice.

Investigators studying old flies have gained some new insight into retinal degeneration, seeking an understanding "of the molecular mechanisms that drive age-associated changes and the external and internal factors that influence them.”

Rich Small, CEO of Neurotech, provides updates on the company’s pipeline that is the culmination of nearly 2 decades of research.

New World Medical notes that the intuitively designed Streamline features ClickPulse technology that targets the eye’s conventional outflow pathway.

Results from the study were presented by Russell Tait, PhD, CEO of PolyActiva, at the Glaucoma 360 New Horizons Forum in San Francisco, California

Utilizing new technology, surgeons can be 20 to 40 times more precise.

During the Glaucoma 360 New Horizons Forum at the Grand Hyatt San Francisco at Union Square, several speakers discussed the latest advances in technology.

Oluwatosin U. Smith, MD, associate professor in the Department of Ophthalmology, University of Texas Southwestern, Dallas, speaks with Ophthalmology Times'® Sheryl Stevenson on the highlights of her presentation exploring remote monitoring of glaucoma and the future of virtual care on the whole.

Andrew G. Iwach, MD, co-founder and co-chair of Glaucoma 360, Glaucoma Center of San Francisco, speaks with Ophthalmology Times’® Sheryl Stevenson on his presentation regarding trends and challenges of glaucoma.

Shan C. Lin, MD, explains why ophthalmologists should be mindful of refractive considerations in cataract surgery for their patients with glaucoma.

Robert L. Stamper, MD, speaks with Ophthalmology Times®' David Hutton on intraocular pressure measurement, corneal elasticity, and why hysteresis is important for glaucoma management.

This year's Shaffer-Hetherington-Hoskins Lecture keynote speaker Joseph Caprioli, MD, focuses on the phenotypes of primary open-angle glaucoma with Ophthalmology Times®' David Hutton at Glaucoma 360.

During the Glaucoma 360 New Horizons Forum, the spotlight was cast upon sustained release injectables, including innovations that have been flourishing over the past year despite, or perhaps because of, a continuing worldwide pandemic.

Robert L. Stamper, MD, speak with Ophthalmology Times®' David Hutton to discuss his presentation at the Glaucoma 360 event in San Francisco, where he presented an update on OCT-Angiography and its role in detecting the density of the capillaries in the macula.

The introduction of new devices is possibly the single most influential factor currently driving the glaucoma market, said Kristen Harmon Ingenito, MBA, in her presentation during the New Horizons Forum at the 2022 Glaucoma 360.

Ranya Habash, MD, medical director of Technology Innovation, assistant professor of Clinical Ophthalmology at Bascom Palmer Eye Institute, University of Miami in Miami, Florida, offers a preview of her New Horizons keynote speech on "The future of eye care: science fiction to science fact."

Ora Chief Medical Officer Gustavo De Moraes, MD, PhD, MPH, speak with Ophthalmology Times®' Sheryl Stevenson to discuss some of the cutting-edge advancements in therapies and diagnostics for the treatment of glaucoma patients.

Glaucoma 360 is being held at the Grand Hyatt San Francisco at Union Square, and the meeting brings together celebration, innovation, and education in its efforts to eradicate glaucoma, with the Gala serving as the traditional kickoff of the event.